SEC Form 4 · accession 0001203311-17-000030
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Jun 5, 2017
Accepted (ET)
Jun 7, 2017 · 7:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2017 | M | 663 | $10.29 | A | 637,098 | D | |
| Common StockF3,F1 | Jun 5, 2017 | S | 663 | $65.82 | D | 636,435 | D | |
| Common StockF1 | Jun 5, 2017 | M | 9,760 | $10.29 | A | 646,195 | D | |
| Common StockF4,F1 | Jun 5, 2017 | S | 9,760 | $65.17 | D | 636,435 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $10.29 | Jun 5, 2017 | M | 663 | D | — | Aug 28, 2017 | Common Stock | 663 | 30,596 | D |
| Non-Qualified Stock Option (right to buy)F5 | $10.29 | Jun 5, 2017 | M | 9,760 | D | — | Aug 28, 2017 | Common Stock | 9,760 | 20,836 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $65.69 to $66.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $64.66 to $65.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.